Novel light-sensitive drug induces sleep without genetic modification

FHS
May 28, 2024
5:41 pm

The nucleus accumbens plays a pivotal role in motivational behavior and sleep regulation, modulated by adenosine A2A receptors (A2AR).

Ligand agrees to acquire APEIRON Biologics for $100m

QARZIBA is indicated to treat high-risk neuroblastoma in patients aged 12 months and above. Credit: Kateryna Kon/Shutterstock. Ligand Pharmaceuticals has announced a definitive agreement for

July 9, 2024

Acupuncture reduces hot flashes and side effects of endocrine therapy in women with breast cancer

In a pooled analysis of three clinical trials, acupuncture significantly reduced hot flashes and other hormonal side effects of endocrine therapy taken by women with

June 24, 2024

Fixing America’s health insurance woes is ‘actually very simple,’ says leading economist

Fixing the U.S. health care system can seem like a herculean task. But the solution is “actually very simple,” according to Massachusetts Institute of Technology

October 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.